In this regard, TF-targeted therapeutics with ability to target three major tumor compartments, i.e., CSCs, cancer cells and tumor neovasculature, may achieve better efficacy and clinical outcome for cancer patients than those that only target CSCs, cancer cells or tumor angiogenesis/neovasculature alone. Here, TF is linked to cancer.